CAITLIN BATMAN: Open Payments
NPI 1396078150 · CUMBERLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,575 in 123 payments from 12 companies in 2025. Trend: 2023 $790 · 2024 $1,608 · 2025 $2,575
Food & beverage: $2,575
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 49 | $612 |
| Teva Pharmaceuticals USA, Inc. | 15 | $473 |
| Alkermes, Inc. | 31 | $470 |
| E.R. Squibb & Sons, L.L.C. | 9 | $373 |
| Neurocrine BioSciences, Inc. | 3 | $179 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $178 |
| Indivior Inc. | 2 | $164 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
Products named: VRAYLAR, COBENFY, ARISTADA, UZEDY, INGREZZA, CAPLYTA, SUBLOCADE, AUSTEDO XR.
Industry payments across MD — which companies pay providers there.
